Compare GDV & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDV | TRVI |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | N/A | 2019 |
| Metric | GDV | TRVI |
|---|---|---|
| Price | $28.79 | $17.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $21.55 |
| AVG Volume (30 Days) | 131.9K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.73 | $5.41 |
| 52 Week High | $29.58 | $18.16 |
| Indicator | GDV | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 72.24 |
| Support Level | $28.73 | $10.07 |
| Resistance Level | $28.85 | N/A |
| Average True Range (ATR) | 0.41 | 0.86 |
| MACD | -0.02 | 0.43 |
| Stochastic Oscillator | 42.44 | 87.21 |
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, including Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services, and others.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.